This website uses cookies. For more information please contact us or consult our privacy policy.

Your binder contains too many pages, the maximum is 40.

We are unable to add this page to your binder, please try again later.

This page has been added to your binder.

UK would lose two pharma bodies in event of Brexit, lawyers warn

May 8, 2016, Financial Times

Peter Bogaert and Grant Castle are quoted in a Financial Times article regarding the effect Brexit would have on the UK pharma industry. According to Bogaert, commenting on the important relationship between the European Medicines Agency and the UK’s Medicines and Healthcare Products Regulatory Agency, “Brexit would be a loss for both sides.”

Castle adds that the presence of the EMA enhanced the appeal of the UK as a place for pharma companies to invest. “That attractiveness would likely diminish outside of the European legislative landscape,” he says.

Share this article: